Clinical ResearchCardiometabolic RiskSpironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
Cardiometabolic Risk
Under an Elsevier user license
open archive
Key Words
cardiovascular and cerebrovascular event
hemodialysis
spironolactone
Abbreviations and Acronyms
ACEI
angiotensin-converting enzyme inhibitor
ARB
angiotensin receptor blocker
CCV
cardiovascular and cerebrovascular
CI
confidence interval
CT
computed tomography
CTR
cardiothoracic ratio
ESRD
end-stage renal disease
HD
hemodialysis
HR
hazard ratio
MRI
magnetic resonance imaging
RAAS
renin-angiotensin-aldosterone system
SCD
sudden cardiac death
TIA
transient ischemic attack
Cited by (0)
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.